Coya Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Coya Therapeutics, Inc. (COYA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $943.91 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $943.91K, a 8.86% decline year-over-year.
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.20M, a 103.27% increase year-over-year.
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.07M, a 38.18% increase year-over-year.
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.04M.
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $207.35K, a 11.10% decline from fiscal 2021.
- Coya Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $233.22K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $943.91K 10-Q · filed 2026-08-11 | $3.14M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $2.20M 10-Q · filed 2026-08-11 | |||
| 2025-09-30 | $1.07M 10-Q · filed 2025-11-12 | $2.11M derived: sum of 2 quarters · filed 2026-08-11 | $3.19M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.04M 10-Q · filed 2026-08-11 | $2.12M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.08M 10-Q · filed 2026-08-11 | |||
| 2024-09-30 | $775.01K 10-Q · filed 2025-11-12 | |||
| 2024-03-31 | $435.66K 10-Q · filed 2025-11-12 | |||
| 2023-09-30 | $262.75K 10-Q · filed 2024-11-06 | $453.86K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $191.11K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $207.35K 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $69.83K 10-Q · filed 2023-11-08 | $114.49K derived: sum of 2 quarters · filed 2023-11-08 | $135.92K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $44.66K 10-Q · filed 2023-11-08 | $66.08K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $21.43K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $233.22K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |